CARsgen Therapeutics CEO on H.K. Trading Debut, Strategy

The video discusses the current state and future of CAR T cell therapies, focusing on a leading company's achievements, regulatory challenges, and potential collaborations. Despite the crowded market, the company remains optimistic about approvals and reducing costs to make therapies more accessible. The discussion also covers risk-reward analysis and the company's strategic plans for global trials and partnerships.

What challenges does the speaker identify in negotiating with big pharma companies?

How does the speaker plan to make cell therapies more accessible and affordable?

What are the potential benefits of treating a larger number of patients with cell therapies?